Samuel B. Fordyce

Samuel B. Fordyce

Auto-generated profile, based on publicly available information

Samuel B. Fordyce

Columbia University Irving Medical Center

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
ASAbin Sajan
Abin Sajan
SFSamuel Fordyce
Samuel Fordyce
ASAndrew Sideris
Andrew Sideris
CLConnie Liou
Connie Liou
ZTZeeshan Toor
Zeeshan Toor
JWJoshua Weintraub
Joshua Weintraub
Uveal melanoma is one of the most common primary intraocular malignancies that accounts for about 85% of all ocular melanomas. The pathophysiology of uveal melanoma is distinct from cutaneous melanoma and has separate tumor profiles. The management of uveal melanoma is largely dependent on the presence of metastases, which confers a poor prognosis with a one-year survival reaching only 15%. Although a better understanding of tumor biology has led to the development of novel pharmacologic agents, there is increasing demand for minimally invasive management of hepatic uveal melanoma metastases. Multiple studies have already summarized the systemic therapeutic options available for metastatic uveal melanoma. This review covers the current research for the most prevalent locoregional treatment options for metastatic uveal melanoma including percutaneous hepatic perfusion, immunoembolization, chemoembolization, thermal ablation, and radioembolization.

29 May 2024
Verified
Book Chapter
Closed access
PDF file
SFSamuel B. Fordyce
Samuel B. Fordyce
RPRooshi K. Parikh
Rooshi K. Parikh
SRStephen Reis
Stephen Reis